Clinical Trials
8 trialsNCT01480154 2026-04-13
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01344031 2018-07-23
MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01263145 2017-08-25
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01783171 2017-08-22
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT01281163 2015-08-27
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01245205 2014-10-23
Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01231919 2014-04-29
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT01705340 2013-09-30
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Terminated